View in EDS

Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective.

Saved in:
Bibliographic Details
Title: Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective.
Authors: Wiethoff I; Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands. i.wiethoff@maastrichtuniversity.nl., Witlox WJA; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+, Maastricht, The Netherlands., Evers SMAA; Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.; Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Centre for Economic Evaluation, Utrecht, The Netherlands., Michels M; Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thorax Center, Rotterdam, The Netherlands., Hiligsmann M; Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
Source: PharmacoEconomics [Pharmacoeconomics] 2026 Feb; Vol. 44 (2), pp. 245-259. Date of Electronic Publication: 2025 Nov 20.
Publication Type: Journal Article; Comparative Study
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2027 (Electronic) Linking ISSN: 11707690 NLM ISO Abbreviation: Pharmacoeconomics Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-2027
DOI:10.1007/s40273-025-01564-2